Cochrane Airways Group,
Further research must clarify subgroups of people who could benefit: also dosage, dosing regimens
Further research must clarify subgroups of people who could benefit: also dosage, dosing regimens
Heterogeneity in severity- from mild to moderate atopic asthma, to persistent
7 studies involved IV mepolizumab; 1 had a subcutaneous arm. http://ow.ly/Qaqc9
8 studies on 1707 participants included. Only 2 studies included adolescents, but did not report separate findings http://ow.ly/Q…
Mepolizumab: a monoclonal antibody against IL-5 a cytokine which activates eosinophils, and cause airway inflammation http://ow.l…
New #Cochrane Review: Mepolizumab versus placebo for asthma http://ow.ly/QalOf